BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 24016394)

  • 1. Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma.
    Tao CJ; Liu X; Tang LL; Mao YP; Chen L; Li WF; Yu XL; Liu LZ; Zhang R; Lin AH; Ma J; Sun Y
    Chin J Cancer; 2013 Oct; 32(10):525-32. PubMed ID: 24016394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
    Han L; Lin SJ; Pan JJ; Chen CB; Zhang Y; Zhang XC; Liao XY; Chen QS
    Chin J Cancer; 2010 Feb; 29(2):145-50. PubMed ID: 20109341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definitive intensity-modulated radiation therapy for nasopharyngeal carcinoma: long-term outcome of a multicenter prospective study.
    Wang R; Wu F; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):139-45. PubMed ID: 22986812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone.
    Su SF; Han F; Zhao C; Chen CY; Xiao WW; Li JX; Lu TX
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):327-33. PubMed ID: 21035959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.
    Lertbutsayanukul C; Prayongrat A; Kannarunimit D; Chakkabat C; Netsawang B; Kitpanit S
    Strahlenther Onkol; 2018 May; 194(5):375-385. PubMed ID: 29302704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events.
    Songthong AP; Kannarunimit D; Chakkabat C; Lertbutsayanukul C
    Radiat Oncol; 2015 Aug; 10():166. PubMed ID: 26253488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
    Lee N; Harris J; Garden AS; Straube W; Glisson B; Xia P; Bosch W; Morrison WH; Quivey J; Thorstad W; Jones C; Ang KK
    J Clin Oncol; 2009 Aug; 27(22):3684-90. PubMed ID: 19564532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma.
    Yi J; Huang X; Gao L; Luo J; Zhang S; Wang K; Qu Y; Xiao J; Xu G
    Radiat Oncol; 2014 Feb; 9():56. PubMed ID: 24533569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study.
    Wang J; Shi M; Hsia Y; Luo S; Zhao L; Xu M; Xiao F; Fu X; Li J; Zhou B; Long X
    Radiat Oncol; 2012 Jan; 7():2. PubMed ID: 22233756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Kim K; Wu HG; Kim HJ; Sung MW; Kim KH; Lee SH; Heo DS; Kim HJ; Park CI
    Head Neck; 2009 Sep; 31(9):1121-8. PubMed ID: 19340863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer - a retrospective single center analysis.
    Saleh-Ebrahimi L; Zwicker F; Muenter MW; Bischof M; Lindel K; Debus J; Huber PE; Roeder F
    Radiat Oncol; 2013 Jan; 8():20. PubMed ID: 23347410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Niu X; Hu C; Kong L
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):1063-71. PubMed ID: 23525586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience.
    Sultanem K; Shu HK; Xia P; Akazawa C; Quivey JM; Verhey LJ; Fu KK
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):711-22. PubMed ID: 11020568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Wu M; Ou D; He X; Hu C
    Oral Oncol; 2017 Oct; 73():118-123. PubMed ID: 28939063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma.
    Tao CJ; Lin L; Zhou GQ; Tang LL; Chen L; Mao YP; Zeng MS; Kang TB; Jia WH; Shao JY; Mai HQ; Lin AH; Ma J; Sun Y
    PLoS One; 2014; 9(10):e110765. PubMed ID: 25329593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Regression and Patterns of Distant Metastasis of T1-T2 Nasopharyngeal Carcinoma with Intensity-Modulated Radiotherapy.
    Wu MY; He XY; Hu CS
    PLoS One; 2016; 11(4):e0154501. PubMed ID: 27119991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma.
    Zhong YH; Dai J; Wang XY; Xie CH; Chen G; Zeng L; Zhou YF
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1577-83. PubMed ID: 23549883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
    Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
    Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.